Assetmark, Inc Tarsus Pharmaceuticals, Inc. Transaction History
Assetmark, Inc
- $45.6 Billion
- Q3 2025
A detailed history of Assetmark, Inc transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 14 shares of TARS stock, worth $1,010. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14
Previous 14
-0.0%
Holding current value
$1,010
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding TARS
# of Institutions
231Shares Held
45MCall Options Held
51.6KPut Options Held
15.8K-
Black Rock Inc. New York, NY3.27MShares$236 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY3.18MShares$229 Million2.52% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$217 Million5.63% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.67MShares$192 Million5.1% of portfolio
-
Jennison Associates LLC2.6MShares$188 Million0.09% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.92B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...